The proposed bill would amend current statutes to expand the scope of practice for pharmacists in Arizona, allowing them to independently order, perform, and interpret certain FDA-authorized medical tests and initiate treatment for specific conditions without a prescription. This includes conditions such as influenza and COVID-19. The bill mandates the Arizona State Board of Pharmacy to develop a statewide written protocol that outlines necessary documentation, record retention, patient screening, and treatment instructions. It also establishes an independent advisory committee to assist in protocol development and requires adherence to evidence-based clinical guidelines.

While current law regarding the general practice of pharmacy remains unchanged, the bill introduces new provisions that specify eligible health conditions for treatment and outlines responsibilities for pharmacists, including notifying primary care providers after initiating treatment. It prohibits pharmacists from independently initiating opioid treatments or treating minors without parental consent. Additionally, the bill allows for the delegation of certain testing tasks to licensed pharmacy staff under supervision, while ensuring that tasks requiring clinical judgment cannot be delegated. Overall, the bill aims to enhance pharmacists' roles in patient care while maintaining proper oversight and protocols.

Statutes affected:
Introduced Version: 32-1979.04